Contract development and manufacturing organizations (CDMOs) are the foundation of the modern peptide supply chain. The GLP-1 wave overwhelmed legacy SPPS capacity through 2023-2025, and the 2026 CDMO sector is in the middle of its largest capacity buildout in two decades — Bachem (Bubendorf, Vista, Sisslerfeld, St Helens), PolyPeptide (Malmö, Braine-l'Alleud, San Diego), CordenPharma ($200M+ Swiss greenfield plus the AmbioPharm acquisition adding US and Shanghai sites), and a growing tier of Asian CDMO entrants.
The sector is also consolidating along specialty lines. The Indena + Chemi S.p.A. (Italfarmaco) June 2026 partnership pairs peptide chemistry with high-potency API conjugation for the peptide-drug-conjugate modality — one of several deals that reflect how CDMOs are pairing complementary capabilities rather than building everything in-house. The pattern matches CordenPharma's AmbioPharm acquisition, the Bachem strategic-asset April 2026 deal, and Lonza's continued SPPS capacity additions.
The regulatory backdrop tightened in 2026. The EMA's first-ever synthetic peptide guideline (EMA/CHMP/CVMP/QWP/367182/2025) took effect June 1, 2026, codifying manufacturing-route and impurity expectations across human and veterinary peptide APIs. Stories here cover capacity expansions, contract wins, M&A, leadership transitions, and the broader manufacturing economy that determines what the next wave of peptide drugs can be supplied at scale. See #bachem, #polypeptide, #cordenpharma, #peptide-manufacturing, and #manufacturing for adjacent threads.
Shilpa said at the TIDES Europe conference in Amsterdam that it is spending $50 million to expand commercial peptide manufacturing on its export-oriented, 34-acre campus in Raichur, Karnataka, with reactors of up to 1,000 liters and capacity of up to one metric ton a year, BioProcess International reported on November 6. CEO Keshav Bhutada said the commercial line is on track to open in December 2026; the company plans to make GLP-1 peptides, longer peptides for cancer and rare diseases, and more cytotoxic and peptide-conjugate payloads.
Shareholders of PolyPeptide Group, the Swiss contract maker of peptide drug ingredients, approved all board proposals at an extraordinary general meeting in Baar on October 27, 2026. They elected John Chongbo Rim as chair along with Seungho Ryu, Cheol Woo Ryu, Mihyun Yang, and Joonkyung Seong, effective when Samsung Peptide AG, a Samsung Biologics subsidiary, settles its public tender offer. Shareholders also voted to remove limits on share transfers and voting rights from the company's articles, subject to the offer's conditions.
Samsung Peptide AG, a subsidiary of Samsung Biologics, published a provisional interim result on October 13, 2026 after its main offer period for PolyPeptide Group ended on October 12: 29,014,418 shares, or 87.88% of the shares covered by the CHF 44.31-per-share offer, were tendered, well above the 66.7% minimum, including all 18,375,000 shares held by the largest shareholder, Draupnir Holding, according to the Asia Business Daily. The audited interim result is due October 16, an additional acceptance period runs October 19 to 30, and closing awaits regulatory approvals in Europe, India, Australia, and Brazil, with completion targeted for the end of November.
Contract manufacturer SK pharmteco announced on Wednesday, September 30, 2026 a five-year investment of more than $200 million in its U.S. development and manufacturing operations, centered on its Rancho Cordova, California site. The plan adds GMP kilo-scale peptide manufacturing with advanced liquid chromatography, expected to be operating in late 2026, along with new small-molecule API suites and about 100 long-term U.S. jobs. CEO Joerg Ahlgrimm said the expansion responds to 'unprecedented demand from our broad customer base.'
Lonza (SIX: LONN) reported first-half 2026 earnings Wednesday July 22, 2026: sales of CHF 3.37 billion (up 11.2% at actual exchange rate, up 16.0% at constant exchange rate), CHF 595 million profit (CHF 8.18 per share) versus CHF 426 million (CHF 5.68 per share) in H1 2025, and CHF 1.2 billion core EBITDA (up 27.4% year-over-year) at a 34.8% margin (up 4.4 percentage points). The Advanced Synthesis division, which houses small-molecule and bioconjugate manufacturing, delivered 27.7% CER sales growth driven by demand for small-molecule and bioconjugate products; the Integrated Biologics division grew 10% CER. Lonza lifted its full-year 2026 margin outlook and confirmed CDMO capacity expansion in Stein, Switzerland following a major-pharma ADC clinical and commercial manufacturing agreement. The Lonza H1 print, combined with the July 20 Samsung Biologics $1.8 billion PolyPeptide tender offer and the July 2 Lonza-Nona Biosciences TfR1 BBB deal, sustains the peptide- and biologic-CDMO consolidation thesis that has run through the first half of 2026. Peptide-based GLP-1 manufacturing capacity constraints continue to drive premium CDMO pricing.
Samsung Biologics announced Sunday-Monday July 19-20, 2026 an all-cash public tender offer to acquire Switzerland's PolyPeptide Group for CHF 1.46 billion ($1.8 billion) at CHF 44.31 per share, a 40% premium to the undisturbed share price of CHF 31.65. The transaction represents the largest biopharmaceutical M&A in South Korean history. Strategic rationale: PolyPeptide is a global peptide contract development and manufacturing organization (CDMO) with accelerating revenue growth driven by rising client demand for peptide-based GLP-1 therapies for obesity and diabetes. The acquisition expands Samsung Biologics' capabilities beyond monoclonal antibody manufacturing (its historical strength) into peptide therapeutics and adds PolyPeptide's global network spanning Sweden, Belgium, France, the United States, and India, encompassing R&D, development, and commercial manufacturing capabilities. PolyPeptide's Board of Directors unanimously recommends the offer. The largest shareholder has given an irrevocable tender undertaking representing approximately 55.65% of outstanding shares. Samsung Biologics expects to complete the deal by end of 2026. The deal extends the July 2026 peptide-manufacturing consolidation wave alongside Novartis's $1.5 billion Myricx Bio acquisition (ADC payloads, July 6) and Lonza's Nona Biosciences TfR1 blood-brain-barrier deal (July 2).
Lonza announced Thursday July 2, 2026 that it has acquired rights to Nona Biosciences' transferrin receptor 1 (TfR1) blood-brain barrier (BBB) technology and expanded its strategic collaboration with Nona to develop next-generation BBB delivery platforms. The technology uses single-domain VHH antibodies that bind TfR1, a receptor expressed on the cells lining the blood-brain barrier, to shuttle attached payloads into the brain. The platform can deploy as an immunoglobulin G (IgG) fusion or through conjugation with therapeutic molecules using Lonza's GlycoConnect bioconjugation technology. Preclinical data show that Nona's TfR1-binding VHH improved brain delivery versus a leading industry benchmark in a relevant transgenic model. Financial terms were not disclosed. Under the agreement, Lonza will immediately make the technology available to CNS drug developers while continuing to collaborate with Nona on future BBB platforms. The deal fits Lonza's CDMO-facing strategy of combining GS Gene Expression System capabilities with GlycoConnect chemistry to give customers new tools for CNS therapeutic candidates — including peptide-and-conjugate CNS programs that have historically been limited by BBB penetration.
Indena and Chemi S.p.A. (Italfarmaco Group) announced a strategic partnership in June 2026 combining peptide chemistry and high-potency API (HPAPI) conjugation expertise to position both firms as development and manufacturing partners for biotech and pharmaceutical companies pursuing peptide-drug conjugates (PDCs). Under the agreement, Chemi supplies the peptide carrier molecules and Indena handles the conjugation with highly potent payload molecules. Neither company is developing proprietary PDC drugs; the partnership reflects the broader CDMO consolidation pattern as the PDC modality scales (six PDCs in Phase 3 trials and ~96 in development globally per the April 2026 ResearchAndMarkets report, with Lutathera as the only FDA-approved standalone PDC after Pepaxto's withdrawal and the Pepaxti EMA expansion application pending). The partnership lands alongside CordenPharma's AmbioPharm acquisition and the broader sector reshaping.
Catalent's TIDES USA 2026 presence centers on oral macromolecule delivery — the bottleneck that has kept all but a handful of peptides off the oral-route market. The contract development and manufacturing organization is showcasing its Zydis fast-dispersion platform, ZipDose 3D-printed dose-form technology, and oral macromolecule delivery systems engineered for peptides and proteins up to ~100,000 Da. The portfolio targets the post-orforglipron oral-GLP-1 reference architecture: SNAC permeation enhancers (Novo Nordisk's oral semaglutide approach), lipidation chemistry, and protective formulation matrices. Catalent's positioning aligns with the broader CDMO build-out — PolyPeptide's May EUR 200M credit facility, CordenPharma's $500M Boulder SPPS expansion — converging on Boston this week.
Swiss peptide CDMO Bachem announced a strategic partnership and asset acquisition in April 2026 to scale large-scale peptide API production. The move responds to surging demand for GLP-1 and next-generation peptide drugs — the global peptide synthesis market is now projected to reach $2.26 billion by 2033 at an 11.4% CAGR. Bachem previously secured a CHF 1 billion peptide supply contract and is operating three site expansions to address capacity constraints that have periodically disrupted semaglutide and tirzepatide supply.